Bayer announced that it has updated the labels for its drospirenone-containing combination oral contraceptives (COCs) in the United States.
The updates include additional information from recent studies evaluating the risk of venous thromboembolism (blood clots) in women taking drospirenone-containing COCs. It specifically states that these COCs may be associated with a higher risk of venous thromboembolism (VTE) than COCs containing levonorgestrel or some other progestins. In addition, the revised labels update information that there is a risk of VTE among all COCs, but that the risk of VTE associated with pregnancy is even greater than the risk associated with any COC use, including drsp-containing COCs.
For more information call (800) 288-8371 or visit www.bayer.com.